Overview
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
Status:
Recruiting
Recruiting
Trial end date:
2023-09-30
2023-09-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of RO7017773 in participants aged 15-45 years who have been diagnosed with ASD with a score of >/=50 on the Wechsler Abreviated Scale of Intelligence (WASI-II).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La Roche
Criteria
Inclusion Criteria- Male and female participants with Autism Spectrum Disorder according to Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- Wechsler Abbreviated Scale of Intelligence (WASI-II) >/= 50 at screening or within the
last 12 months prior to screening
- ASD or Autism diagnosis confirmed by Autism Diagnostic Observation Schedule (ADOS-2)
- Body mass index within the range of 18.5 to 40 kg/m2
- Female Participants: is eligible if she is not pregnant, not breastfeeding, and women
of childbearing potential (WOCBP), who agree to remain abstinent or use contraceptive
methods that result in a failure rate of < 1% per year during the treatment period and
for at least 28 days after the last dose of study drug
- Language, hearing, and vision compatible with the study measurements as judged by the
Investigator
- Allowed existing treatment regimens should be stable for 8 weeks prior to screening.
Investigator expects stability of these treatments and behavioral interventions for
the duration of the study
- In the Investigator's opinion, able to participate and deemed appropriate for
participation in the study, capable of following the study SoA and able to comply with
the study restrictions
- In the Investigator's opinion, participation in the study or discontinuation of
prohibited medication will not pose undue risks
Exclusion Criteria
Neurologic/Psychiatric Conditions:
- Non-verbal individuals
- Presence of chromosome 15q11.2 q13.1 duplication syndrome (Dup15q syndrome)
genetically defined ASD per genetic results available prior to screening or known
"syndromic" forms of ASD (e.g., fragile X syndrome, Prader Willi syndrome, Rett's
syndrome, or tuberous sclerosis).
- Medical history of alcohol and/or substance abuse/dependence in the last 12 months or
positive test for drugs of abuse at screening
- Initiation of a major change in psychosocial intervention within 6 weeks prior to
screening. Minor changes in ongoing treatment are not considered major changes
- Clinically significant psychiatric and/or neurological disorder that may interfere
with the safety or efficacy endpoints
- Risk of suicidal behavior in the opinion of a certified clinician or as evidenced by a
"yes" to questions 4 and/or 5 of Columbia-Suicide-Severity Rating Scale (C-SSRS) taken
at screening and baseline with respect to the last 12 months, or any suicide attempt
in the past 5 years
- Unstable epilepsy/seizure disorder within the past 6 months or changes in
anticonvulsive therapy within the last 6 months
Other Conditions:
- Medical history of malignancy if not considered cured or if occurred within the last 3
years with the exception of fully excised non-melanoma skin cancers or in-situ
carcinoma of the cervix that has been successfully treated
- Concomitant disease, condition or treatment which would either interfere with the
conduct of the study or pose an unacceptable risk to the participant in the opinion of
the Investigator Prior/Concomitant Therapy
- Use of prohibited medications or herbal remedies within 6 weeks or 5 half-lives (t1/2)
prior to randomization
Prior/Concurrent Clinical Study Experience:
- Donation or loss of blood over 500 mL in adults and 250 mL in adolescents within 3
months prior to randomization
- Participation in an investigational drug study within 1 month or 5 times the t1/2 of
the investigational molecule prior to randomization or participation in a study
testing an investigational medical device within 1 month prior to randomization or if
the device is still active Diagnostic Assessments
- Confirmed clinically significant abnormality in hematological, chemistry or
coagulation laboratory parameters
- Positive test result at screening for hepatitis B surface antigen, hepatitis C virus
(HCV, untreated), or human immunodeficiency virus (HIV)-1 and -2. HCV participants who
have been successfully treated and who test negative for HCV RNA, may be considered
eligible for entry into the study
Other Exculsions:
- Uncorrected hypokalemia or hypomagnesaemia